The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
but yet the share drops......mm's playing around???....what is going to turn sentiment around on this share, as not even two decent rns's have done much....
Bluhope, I agree with you. But I wish they could give some idea about the production and how they plan to ramp it up. Also a rough idea on when the product is due to come to market.....
But patiently waiting....
GS, The company have said that they want to do a deal with companies that will grow the product over time to get brand "loyalty"...this takes time.....
I am in profit and got over 260000 shares and in no hurry and will slowly reduce my holdings to pay my bills (as just retired) so I like that FUM will take a long term view (the one thing that FUM management and I do agree on)....
I also like we've only had a few posts, as it means LB isn't spouting rubbish and everyone responding. Most of the time on the board these days is only a few posts are anything different...
GS - I agree with your statement and unlike some on this BB i prefer caution, especially with an AIM stock. I also think FUM Management have been on the gravy train too long. But do think MED will be a big seller, once they get a proper deal.
I was against the way FUM did this placing, but after much swearing do believe it's a good thing as now they have enough money for a while, so they can take their time on making a good deal.
Hoping it doesn't go down to 30p, but then I will still be in profit.
guess jackbogle is another tnuc that needs to be filtered....
no need to reply jackbogle as I can't read it....
I don't believe the share will drop to 25p personally, but it will drop......but it will take longer than we thought it would to get to liberum's prices of 80p and beyond....
when you do reread it, there is some good news. The share will drop to 40p and maybe lower on Monday. At least they are giving the PI to get some shares (assuming you have money which I don't).
But to drop this on Friday afternoon is an utter disgrace. The CFO is certainly not fit for the job, as far as I am concerned. She should be making deals not screwing the LTH shareholders. It's not the first time she has royal **c*ed us.
very hard to judge what are buys and sells.
I just bought a few more at .017944 and it's showing as a sell...wonder how many more are actual buys but showing as sells....
when I go to ADFVN charts and put in ECR with data range of 2004 (when it became public) and 2021 it does say share price was £20....but it had a split of 10/1 in 2006 and then 2016
https://uk.advfn.com/stock-market/london/ecr-minerals-ECR/chart/real-time
Use the link and put in 2004 to 2021......
hadn't seen that article.....so thanks...
I also can't find the one mentioned by Stokie
Has anybody found any articles on any websites about the CE certificate, as I haven't seen any
Although I'd prefer preferential terms for FUM, I want the companies (they do deals with ) to spend some money to get this product well known. To advertise etc costs a lot of money and you can't rely on word and mouth (although that will be help).
FUM have had previous issues with past products, that sounded good, but due to lack of spending (hence exposure) didn't do much.
Lets hope there experience from past products will pay off. Seeing as they've got a specialist company helping them is a good start.....
I don't normally advise friends about shares but I have been telling friends about this product. GLA as I'm very bullish about this product....well I would be as my average price is 26p and not selling any until I see at least £1...
great news about the certificate. Now received hopefully we'll get some deals soon, which should be good for the share price....gla
there is no guarantee it will be the end of May.....especially during the Covid stuff etc etc....but let' s hope so....
it returned in Feb 2021 being paid May 19th.....they aren't paying a quarterly divi as bank are being cautious due to the regulation body. We'll get more information at half year report
liked reading this on the Guardian Website about HSBC releasing monies put aside for bad debts.
The bank released $400m of provisions that it had set aside for bad debts racked up during the pandemic, “particularly in the UK”, reflecting improved economic forecasts.
Hope Lloyds will do something similar..
With GSK shares not doing well and needing to improve it's bottom line, could they take a look at FUM....as the subject say, far fetched. If they can market this right in the EU, with lots of advertising, then who knows....
https://www.theguardian.com/business/2021/apr/25/glaxosmithkline-faces-dose-of-strong-medicine-from-us-investor
When the American hedge fund Elliott Management took a sizeable stake in GlaxoSmithKline this month, the drugmaker’s shares jumped 5% on speculation of a possible shake-up at the company.
GSK’s chief executive, Emma Walmsley, will face questions over the future of the business, as well as its performance, when she unveils first-quarter results on Wednesday, followed by the annual meeting a week later. Analysts are forecasting a 14% drop in revenues to £7.8bn and a 10% decline in pre-tax profit to £1.7bn in what looks to be the weakest quarter of the year. This reflects tougher year-on-year comparisons (due to stockpiling of many products at the start of the pandemic), as well as rising research and development costs.
Elliott is a prominent activist investor that has successfully campaigned for change at companies such as SoftBank, and is infamous for its 15-year battle with Argentina over government debt payments, but it is unclear what its intentions are this time, as GSK is about to be broken up anyway under a radical revamp thought up by Walmsley.
A sale of the business also looks unlikely, as “the UK government would be highly unlikely to allow a foreign company to take over GSK, and that would really be the only feasible option, given the company’s size,” says Barclays analyst Emily Field. “Elliott may be seeking management change, but thus far it would seem management has the full support of the board.”
Next year, GSK – a household name whose products range from Sensodyne toothpaste and Panadol painkillers to HIV treatments and the Shingrix shingles vaccine – will be split into a consumer healthcare and a pharmaceuticals business. The latter will be created from the HIV, vaccines and pharma divisions.
Analysts say the key part is the creation of a single biopharma business focused on developing new medicines and vaccines from biological and chemical sources, because here GSK’s pipeline lags behind rivals after a series of setbacks in the past year. It is in a similar position to where AstraZeneca was a few years ago, before its chief executive, Pascal Soriot, set about rebuilding its drugs portfolio and made smart research bets, particularly on cancer treatments.
Elliott’s investment piles more pressure on Walmsley to get the revamp right – and to come up with new blockbuster drugs. She is likely to face questions about who will lead the two new businesses after the split. She wants to run the biopharma company, but some investors appear to question her non-scientific background and would reportedly prefer her to head the consumer health business, which she led before her elevation to c
well at least we know why we've seen the share price drop a bit...wonder how much Lombard are offloading....as could drag the price down lower (well without news that we know are coming).....
Victoria cancel the BRI with China
https://edition.cnn.com/2021/04/22/business/australia-china-belt-and-road-initiative-intl-hnk/index.html
The Australian government has canceled a Belt and Road agreement signed by China and the state government of Victoria, escalating trade and diplomatic tensions between Beijing and Canberra.
Victoria — the country's second largest and wealthiest state — signed a memorandum of understanding on the Belt and Road Initiative (BRI) with the Chinese government in October 2018, the only government in Australia to sign up for Chinese President Xi Jinping's signature global infrastructure initiative.
Part of Xi's vision for China's future economic growth, the BRI is intended to build new trade corridors between Europe and Asia, following the path of the historic silk road. While other countries that have joined the BRI have received large scale funding from Beijing, the deal between China and Victoria appeared to be aimed more at encouraging future investment and trade.
In a statement Wednesday night, Foreign Minister Marise Payne said the federal government had evaluated "more than 1,000" deals between Australia's states and territories and foreign governments.
In total, four deals were canceled, two with China and one each with Iran and Syria, all signed by the Victorian government.
"I consider these four arrangements to be inconsistent with Australia's foreign policy or adverse to our foreign relations," Payne said in her statement.
The move was made under new a legislation passed last December, which experts saw as squarely targeted at the deal between Victoria and China.
Speaking to Australian radio on Thursday, Payne said the decision wasn't directed at any particular country. However the Chinese embassy in Australia denounced the cancellation in a statement, expressing Beijing's "strong displeasure and resolute opposition."
"This is another unreasonable and provocative move taken by the Australian side against China. It further shows that the Australian government has no sincerity in improving China-Australia relations," the statement said, adding that the cancellation will only "further damage" relations between the two countries.
China and Australia are already in the middle of a worsening diplomatic crisis, with relations between the two governments at record lows since Canberra's call for an international investigation into the origins of Covid-19 in April 2020.
Since then, millions of dollars of Australian imports have encountered difficulties entering the Chinese market, including timber, beef and some types of coal. In March, the Chinese government confirmed that Australian wine would face tariffs of up to 218% for five years due to allegations of "dumping and [market] damage."
Overall, Chinese investment in Australia dropped by 62% in 2020, down to just $775 million.
What I have an issue with CB is, he still hasn't said why he needed to raise more capital if they had enough money to last until 2023.....